Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual
Revitalist Lifestyle and Wellness LTD. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) recently announced a new joint venture partnership with Wake Network, Inc.
Psychedelic biopharmaceutical company Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announced today the dosing of the first two patients in the company’s Phase
Biopharmaceutical company Short Wave Pharma Inc. has announced a signed Clinical Trial Agreement with the Sheba Fund for Health Services and Research. Dr. Eitan
Field Trip Health & Wellness Ltd. announced today that the company has filed the necessary listing application to list its common shares
Clinical‐stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) today announced the company’s participation in Project Solace, the
Evidence-based mental healthcare company Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announced that its wholly-owned subsidiary KGK Science Inc. has entered into
Zylorion announced today the filing of the Company’s third provisional patent application with the United States Patent and Trademark Office (“USPTO”). The
Clinical-stage biotechnology Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) has strengthened their intellectual property portfolio with a new provisional patent designed to treat